Olmezest AM: A Combined Antihypertensive for Blood Pressure Control

Olmezest AM is a combination medication indicated for the treatment of hypertension (high blood pressure). It combines two active ingredients, Amlodipine and Olmesartan Medoxomil, to provide a dual mechanism for lowering blood pressure. This combination is particularly indicated as initial therapy for patients likely to require multiple antihypertensive agents to achieve their blood pressure goals.

How Olmezest AM Works (Pharmacology)

Olmezest AM combines the actions of two distinct classes of antihypertensive drugs:

1. Amlodipine (Dihydropyridine Calcium Channel Blocker): Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Its primary effect is on vascular smooth muscle cells, where it acts as a peripheral arterial vasodilator. This direct action on blood vessels causes a reduction in peripheral vascular resistance, leading to a decrease in blood pressure.
2. Olmesartan Medoxomil (Angiotensin II Receptor Blocker - ARB): Angiotensin II is a potent vasoconstrictor and a key hormone in the Renin-Angiotensin System (RAS) involved in hypertension pathophysiology. It also stimulates aldosterone secretion. Olmesartan Medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor found in various tissues, including vascular smooth muscle and the adrenal gland. By blocking this receptor, Olmesartan prevents the vasoconstrictor and aldosterone-secreting effects of angiotensin II, thus lowering blood pressure. Olmesartan Medoxomil is a reversible, competitive inhibitor of the AT1 receptor and importantly, does not inhibit ACE (the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin).

The combination of Amlodipine's vasodilation and Olmesartan's RAS blockade provides a comprehensive approach to blood pressure control.

Key Indications & Benefits

Olmezest AM is indicated for:

• Treatment of hypertension (alone or with other antihypertensive agents) to lower blood pressure.
• Initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. (The decision for initial combination therapy should be individualized based on factors like baseline blood pressure, target goal, and likelihood of achieving goal with combination therapy).

Dosage & Administration

Dosage should be individualized. Always consult a registered physician for medication use.

• Substitution Therapy: For patients already on individually titrated components of Amlodipine and Olmesartan Medoxomil, this combination can substitute those. The dosage can be further increased with Amlodipine, Olmesartan Medoxomil, or both, as needed.
• Initial Therapy:
  • Initiate with 5/20 mg once daily for 1 to 2 weeks.
  • Titrate as needed up to a maximum of 10/40 mg once daily.
• Elderly Patients (over 75 years):
  • Due to decreased clearance of Amlodipine in elderly patients, the recommended starting dose of Amlodipine as a single agent is 2.5 mg.
  • However, the lowest dose of the combination (Olmezest AM) is 5/20 mg. Therefore, initial therapy with Olmezest AM is not recommended in patients >75 years old.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Olmezest AM.

Contraindications:

• Cannot be co-administered with Aliskiren in patients with diabetes.
• Pregnancy (especially 2nd and 3rd trimesters).

Side Effects:

• Most common: Peripheral edema (swelling, often in ankles/feet), headache, flushing, and dizziness.
• Other: Intestinal problems known as sprue-like enteropathy (a severe, chronic diarrhea with significant weight loss, can occur rarely).

Pregnancy & Lactation:

• Pregnancy Category D.
• Amlodipine and Olmesartan Medoxomil combination should not be used in the 2nd and 3rd trimesters because drugs that act on the renin-angiotensin system (like Olmesartan) can cause fetal injury and even death.
• When pregnancy is detected, this combination should be discontinued as soon as possible.
• Lactation: It is not known whether Olmesartan and Amlodipine are excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the drug's importance to the mother.

Precautions & Warnings:

Olmezest AM should be used with caution due to the risk for:

• Hypotension (low blood pressure) in volume- or salt-depleted patients.
• Vasodilation in patients with severe aortic stenosis.
• Increased frequency, duration, or severity of angina or acute myocardial infarction (heart attack) in patients with severe obstructive coronary artery disease (a potential rare side effect with calcium channel blockers).

Use in Special Populations:

• Pediatric use: The safety and effectiveness have not been established in pediatric patients.
• Geriatric use: No overall differences in safety or effectiveness were observed between subjects 65 years of age or older and younger subjects in studies, except for the specific initial dose consideration due to Amlodipine clearance.
• Renal impairment: There are no specific studies in patients with renal impairment mentioned. Caution is advised as both components can affect renal function.
• Hepatic impairment: Initial therapy with this combination is not recommended in hepatically impaired patients.

Drug Interactions:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors:
  • The antihypertensive effect of angiotensin II receptor antagonists (like Olmesartan Medoxomil) may be attenuated (reduced) by NSAIDs.
  • In elderly, volume-depleted patients (including those on diuretic therapy), or those with compromised renal function, co-administration of NSAIDs (including COX-2 inhibitors) with ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
  • Blood pressure, renal function, and electrolytes should be closely monitored in patients on combination therapy and other agents that affect the Renin-Angiotensin System (RAS).
• Aliskiren: Co-administration with Aliskiren is contraindicated in patients with diabetes.

Overdose Effects:

• There is no specific information on overdose in humans provided. In case of suspected overdose, seek immediate medical attention, and supportive symptomatic treatment would be initiated.

Storage Conditions

Do not store above 30°C. Keep away from light and out of the reach of children.